AbCellera Biologics Inc vs Kraft Heinz Co — how do they compare? AbCellera Biologics Inc trades at $8.99 (market cap $2.99B), while Kraft Heinz Co trades at $24.63 (market cap $29.23B). The key difference: Kraft Heinz Co is far larger — about 9.8× AbCellera Biologics Inc's market cap, and Kraft Heinz Co pays a 6.49% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | KHC | |
|---|---|---|
Market Cap | $2.99B | $29.23B |
Sector | Health | Consumer Staples |
52-Week High | $9.76 | $28.06 |
52-Week Low | $2.78 | $21.21 |
Enterprise Value | $2.58B | $45.55B |
Dividend Yield | — | 6.49% |
Trailing returns across standard periods
Latest headlines on both assets
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →In July 2015, Kraft merged with Heinz to create the third-largest food and beverage manufacturer in North America behind PepsiCo and Nestle and the fifth-largest player in the world. Beyond its namesake brands, the combined firm's portfolio includes Oscar Mayer, Velveeta, and Philadelphia. Outside North America, the firm's global reach includes a distribution network in Europe and emerging markets that drive around one fifth of its consolidated sales base, as its products are sold in more than 190 countries and territories.
Read more on KHC →